Angitia Biopharmaceuticals
Biotechnology Research
Woodland Hills, CA 1,709 followers
Developing innovative medicines to address serious musculoskeletal diseases
About us
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.
- Website
-
http://www.angitiabio.com
External link for Angitia Biopharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Woodland Hills, CA
- Type
- Privately Held
- Founded
- 2018
- Specialties
- musculoskeletal, rare diseases, bone, cartilage, and muscle
Locations
-
Primary
Get directions
Woodland Hills, CA 91367, US
-
Get directions
188 Kaiyuan Avenue
2F, Building 4
Guangzhou, Guangdong 510530, CN
Employees at Angitia Biopharmaceuticals
-
Mike Arenberg
-
Tom Storey
Head of Business Development at Angitia Biopharmaceuticals
-
Susan Ansaldi
Director of Clinical Data Management | Lead Strategic Oversight, Risk Management, Database Development, Data Analytics
-
Robert Stad
Medical Affairs Pharma & Biotech executive | Consultancy | Osteoporosis and bone related diseases I Inflammation
Updates
-
Great way to end the year! We're excited to announce we've closed our Series C financing! Please visit our website to learn more - https://lnkd.in/gKawUQrE Full Endpoint News article can be found here - https://lnkd.in/eRemgbPV
-
Angitia is Hiring! Now is a great time to join us as we continue in our pursuit to discover and develop breakthrough therapeutics in serious musculoskeletal diseases. Please see job posting below and learn more about us at https://lnkd.in/gfEEYCMP
-
Very exciting day here at Angitia! We've successfully dosed the first patient in ARTEMIS, our phase 2 study of AGA2118, which is a bispecific antibody targeting sclerostin and DKK1 for the treatment of osteoporosis. To learn more about this important milestone please visit https://lnkd.in/gh6tSaVV
-
Angitia successfully presented the first-in-human data on AGA2118 for Osteoporosis at ASBMR 2024! The presentation was met with great enthusiasm, highlighting dose-dependent increases in bone mineral density. CEO, Hua Zhu (David) Ke, said "AGA2118 is the first stage bispecific antibody to target two key regulators of bone metabolism, and our first-in-human data demonstrate clinical proof-of-concept for AGA2118." Dr. Matthew Drake from Mayo clinic presented the FIH study on behalf of the co-authors. Special thanks to Ann Zovein and Yilong Zhang for presenting the preclinical and pharmacokinetics data and to Ricardo Dent and his team who were responsible for developing a high-quality FIH study. For more details, read the full press release here: https://lnkd.in/g-UqCxXi #Osteoporosis #AGA2118 #ASBMR2024
-
-
We’re excited to announce that Angitia has been selected to present data on AGA2118 for Osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2024! To view the press release, visit our website at: https://lnkd.in/gC4KdQ-v